MaxCyte Inc (MXCT)vsStryker Corporation (SYK)
MXCT
MaxCyte Inc
$1.24
+1.64%
HEALTHCARE · Cap: $121.78M
SYK
Stryker Corporation
$274.19
+0.33%
HEALTHCARE · Cap: $105.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 83108% more annual revenue ($25.84B vs $31.05M). SYK leads profitability with a 14.4% profit margin vs -114.8%. SYK earns a higher WallStSmart Score of 67/100 (B-).
MXCT
Avoid30
out of 100
Grade: F
SYK
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MXCT.
Margin of Safety
-19.8%
Fair Value
$229.75
Current Price
$274.19
$44.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Strong operational efficiency at 27.0%
Earnings expanding 44.1% YoY
Generating 1.1B in free cash flow
Areas to Watch
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Altman Z-Score, Market Cap.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
MXCT profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.53 — expect wider price swings.
SYK is growing revenue faster at 9.4% — sustainability is the question.
SYK generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (67/100 vs 30/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?